Plasmodium liver stage antigens

US8318183B2 · kind B2 · utility

Assignees

• Seattle Biomedical Research Institute · US
• The United States of America, as represented by the Secretary of the Army, on behalf of the Walter Reed Army Institute of Research · US
• Philadelphia Health & Education Corporation · US

Inventors

• Patrick Duffy · Washington, US
• Stefan H. I. Kappe · Seattle, US
• Urszula Krzych · Washington, US
• Donald G. Heppner, JR. · Vienna, US
• Lawrence W. Bergman · Lansdale, US
• Vladislav A. Malkov · Seattle, US
• Alice Tarun · Shoreline, US
• Jason P. Wendler · Lincoln, US
• Igor Bacik · Rockville, US

Key dates

• Filing date: Mar 11, 2010
• Grant date: Nov 27, 2012
• Expiry date: Mar 11, 2030

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides isolated liver stage Plasmodium polypeptides comprising an amino acid sequence selected from the group consisting of SEQ ID NOs:1-48 and immunogenic derivatives thereof. The invention also provides isolated nucleic acid molecules encoding the liver stage Plasmodium polypeptides of the invention, compositions comprising one or more liver stage Plasmodium polypeptides of the invention, methods for inducing an immune response against the liver stage Plasmodium polypeptides, and methods for treating and diagnosing liver stage malaria.